STOCK TITAN

Cue Biopharma Inc - CUE STOCK NEWS

Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.

Company Overview

Cue Biopharma Inc (symbol: CUE) is a clinical‐stage biopharmaceutical company at the forefront of innovative immunotherapy. Specializing in developing a novel class of therapeutic biologics, the company designs and engineers agents that selectively engage and modulate disease‐specific T cells. By targeting specific antigen‐expressing cells, Cue Biopharma aims to treat a broad range of cancers and autoimmune disorders while potentially reducing the adverse effects associated with broad systemic immune modulation. The company leverages its proprietary Immuno-STAT platform to create therapies that are not only precise in their action but are also designed to rapidly move from discovery to clinical validation through a streamlined development process.

Innovative Immuno-STAT Platform and Pipeline

The core of Cue Biopharma’s strategy lies in its Immuno-STAT platform, a technology that enables the modification of T cell activity through a customizable peptide exchange mechanism. This approach allows the company to design biologics that are capable of engaging specific T cell populations associated with a variety of disease indications. Unlike traditional treatments that may cause widespread immune activation, the selective targeting minimizes unintended effects, offering an advantage in terms of both safety and efficacy.

Within its diversified pipeline, Cue Biopharma is investigating several product candidates. Its lead candidates, such as CUE-101 and CUE-102, are being developed for oncology applications with a focus on HPV-driven head and neck squamous cell carcinoma and tumors expressing specific markers such as Wilms’ Tumor 1. In parallel, the company is also advancing programs in the autoimmune and inflammatory disease sectors, demonstrating the flexibility of its platform across different therapeutic areas.

Business Model and Clinical Strategy

Operating as a clinical-stage biopharmaceutical company, Cue Biopharma generates revenue primarily through strategic collaborations with industry partners. These collaborations support the company’s advancement of clinical trials and provide an operational runway as its product candidates progress through early-phase trials. The company’s business model emphasizes a cost-efficient approach to drug development by leveraging existing, validated drug frameworks for rapid therapeutic candidate selection and clinical validation.

In the realm of clinical development, Cue Biopharma focuses on designing trials that carefully evaluate both monotherapy and combination therapy strategies. For instance, its approach to pairing CUE-101 with established checkpoint inhibitors in oncology trials is a testament to its commitment to enhancing treatment efficacy. The trial designs incorporate careful dose escalation and expansion strategies that help establish a robust safety and efficacy profile necessary for advancing toward later-stage development.

Competitive Positioning and Industry Relevance

In the competitive and rapidly evolving field of immuno-oncology, Cue Biopharma’s commitment to precision in immune modulation distinguishes its therapeutic approach. By concentrating on the selective activation of disease-specific T cells, the company avoids the pitfalls of broad systemic activation that can lead to significant toxicities in conventional therapies. This strategic focus not only positions the company uniquely among its peers but also underscores its potential to address significant unmet medical needs in oncology and autoimmunity.

The company’s approach also emphasizes flexibility. The ability to rapidly exchange peptides within its Immuno-STAT platform means that Cue Biopharma can efficiently recalibrate its therapeutics to address different antigens relevant to various cancers and autoimmune diseases. This adaptability is critical in an era where precision medicine is rapidly transforming treatment paradigms.

Experienced Leadership and Scientific Expertise

Cue Biopharma is guided by an experienced management team and a board of directors with deep expertise in immunology, immuno-oncology, and biologics development. The leadership team’s track record in drug development, combined with an advisory board comprising renowned scientists and clinicians, enhances the company’s credibility. This collective expertise supports a rigorous, science-driven approach to clinical development and underpins the company’s strategy to transform therapeutic standards in challenging disease areas.

Key appointments and strategic transitions within the company further reflect its commitment to innovative clinical and registrational strategies. Such organizational enhancements are aimed at strengthening the company’s operational capabilities and ensuring that sound scientific and clinical principles continue to guide its development efforts.

Research Collaborations and Strategic Partnerships

Recognizing the importance of collaborative research, Cue Biopharma has established partnerships with prominent pharmaceutical companies and leading academic institutions. These partnerships have facilitated access to advanced research tools and clinical trial infrastructures, thereby accelerating the pace of clinical validation for its product candidates. The collaboration with major industry partners not only enhances resource efficiency but also contributes to a broader validation of its novel therapeutic approach.

These alliances enable the company to integrate diverse expertise, ranging from regulatory affairs to clinical trial management, ensuring that its innovations are rigorously evaluated and refined. Through these strategic engagements, Cue Biopharma further reinforces its position as a dynamic and scientifically robust player in the immunotherapy space.

Key Therapeutic Advantages and Operational Efficiency

The potential therapeutic advantages of Cue Biopharma’s approach are multifold. First, by selectively targeting antigen-specific T cell populations, its biologics offer the promise of improved clinical outcomes with a lower incidence of adverse effects. The rational design of its products—incorporating attenuated interleukin signals to fine-tune immune activation—illustrates a sophisticated approach to overcoming the limitations seen in conventional immunotherapies.

Secondly, the company’s ability to streamline the drug development process through a modular platform design could lead to more efficient clinical validation and cost-effective therapeutic candidate progression. This operational efficiency is central to the company’s long-term mission of transforming therapeutic approaches in both oncology and autoimmunity.

Conclusion

In summary, Cue Biopharma Inc stands as a notable entrant in the biopharmaceutical arena, leveraging advanced immunotherapy techniques to develop precise, selective biologics. With a robust Immuno-STAT platform, a diversified clinical pipeline, and a leadership team endowed with substantial industry experience, the company is methodically addressing some of the most challenging therapeutic areas including cancer and autoimmune diseases. Its strategic collaborations and innovative drug development model are designed to bridge the gap between scientific discovery and clinical application, thereby demonstrating significant potential for establishing new standards in patient care.

This comprehensive profile aims to provide investors, industry analysts, and stakeholders with a clear understanding of Cue Biopharma’s business model, technological advancements, and market positioning. By continuing to focus on precision immunotherapy and strategic clinical development, the company reinforces its commitment to scientific excellence and operational efficiency in an increasingly competitive landscape.

  • Innovative Platform: Utilizes a modular approach to target disease-specific T cells.
  • Diversified Pipeline: Focused on both oncology and autoimmune indications.
  • Strategic Collaborations: Engages in partnerships to accelerate clinical development.
  • Operational Efficiency: Streamlined drug development process reducing timelines and costs.
  • Experienced Leadership: Driven by industry veterans with proven track records.

The detailed overview provided here is intended to serve as a resource that encapsulates the company’s evolving strategy, technological innovation, and competitive edge, forming a solid foundation for understanding Cue Biopharma’s unique contributions to the field of immunotherapy.

Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) reported its Q4 and full year 2024 financial results. The company's collaboration revenue for Q4 2024 was $1.6 million, down from $1.8 million in Q4 2023. Full-year collaboration revenue increased to $9.3 million from $5.5 million in 2023, driven by the Ono Pharmaceutical partnership.

R&D expenses decreased to $7.2 million in Q4 2024 from $10.9 million in Q4 2023, while G&A expenses reduced to $4.0 million from $4.6 million. For the full year, R&D expenses were $36.3 million (down from $40.8 million) and G&A expenses were $14.6 million (down from $16.7 million).

The company appointed new leadership including Lucinda Warren as Chief Business Officer and Daniel Baker as Interim Chief Development Officer. Cue regained worldwide rights for CUE-401, their lead autoimmune program, and advanced CUE-501 development. Cash position stood at $22.5 million as of December 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.67%
Tags
-
Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) has granted an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The award consists of options to purchase 200,000 shares of company common stock at $1.06 per share, based on the closing price on November 25, 2024. The options will vest over two years in four equal installments, starting six months from the grant date, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, announced its participation in a fireside discussion at the Piper Sandler 36th Annual Healthcare Conference in New York, NY, from December 3-5, 2024. The company will present updates on clinical and preclinical programs, along with strategic business and partnering objectives.

The presentation will be delivered by CEO Daniel Passeri on Wednesday, December 4, 2024, from 9:00 AM to 9:25 AM EST. A live webcast will be available, and the recording will be archived for 30 days on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
conferences
Rhea-AI Summary

Cue Biopharma reported Q3 2024 financial results and clinical progress. The company's Phase 1 trial of CUE-101 with KEYTRUDA showed 46% objective response rate and 91.3% 12-month survival in HPV+ head and neck cancer patients. CUE-102 demonstrated 67% disease control rate in pancreatic cancer. Financially, collaboration revenue increased to $3.3M from $2.1M year-over-year, while R&D expenses decreased to $9.4M from $9.9M. The company ended Q3 with $32.4M in cash, expected to fund operations into Q4 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17%
Tags
-
Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) announced key organizational changes with Daniel Baker, M.D., joining as interim chief development officer (CDO) effective November 25, 2024. Dr. Anish Suri will transition from president & chief scientific officer to principal research and immunology advisor. Dr. Baker brings over 20 years of pharmaceutical industry experience, notably serving as Vice President of Immunology R&D at Johnson & Johnson, where he oversaw multiple successful drug developments leading to 15+ regulatory approvals. The transition aims to enhance the company's pipeline development in oncology and autoimmunity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) announced its participation in a fireside chat at the Stifel 2024 Healthcare Conference in New York, scheduled for November 18-19, 2024. The company will present updates on its oncology and autoimmune disease programs, including recent data from Phase 1 clinical trials of CUE-101 and CUE-102 previously presented at SITC 2024.

CEO Daniel Passeri will lead the presentation on Tuesday, November 19, from 1:15-1:45 p.m. EST. The fireside chat will be accessible via webcast and archived for 30 days on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
conferences
Rhea-AI Summary

Cue Biopharma presented updated Phase 1 trial data for CUE-101 and CUE-102 at SITC 2024. CUE-101 combined with KEYTRUDA showed impressive results in head and neck cancer patients, achieving a 46% objective response rate and 91.3% 12-month overall survival. The median overall survival reached 21.8 months, significantly higher than historical data. For CUE-102, results showed a 67% disease control rate in late-stage pancreatic cancer patients, including a partial response with 40% tumor reduction. Both treatments demonstrated favorable safety profiles with no significant toxicity concerns.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
-
Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) announced two presentations at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) in Houston, Texas, from November 6-10, 2024. The presentations will focus on their clinical assets CUE-101 and CUE-102, part of the CUE-100 series.

An oral presentation by Dr. Christine Chung will discuss a phase 1 study of CUE-101 as monotherapy and in combination with pembrolizumab for HPV16+ head and neck squamous cell cancer. A poster presentation by Dr. Dae Won Kim will cover a phase 1 trial of CUE-102 for WT1-positive recurrent/metastatic cancers in HLA-A*0201 positive patients.

The oral presentation is scheduled for November 8, 2024, and the poster will be displayed on November 9, 2024. Both presentations will be available as virtual e-posters from November 7, 2024, to January 7, 2025, and on the company's website from November 8, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.6%
Tags
conferences
-
Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE) has announced the pricing of a $12.0 million public offering. The offering includes 11,564,401 shares of common stock with warrants to purchase 2,891,100 additional shares, and pre-funded warrants to purchase 12,435,599 shares with warrants for 3,108,900 more shares. Each common stock share and warrant combination is priced at $0.50, while the pre-funded warrant and common stock warrant combination is priced at $0.499.

The offering is expected to close around September 30, 2024. Oppenheimer & Co. Inc. is the sole book-running manager, with Newbridge Securities as co-manager. The securities are being offered under a shelf registration statement filed with the SEC. This announcement does not constitute an offer to sell or a solicitation of an offer to buy these securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
49.61%
Tags
Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, has announced a proposed public offering of common stock shares and accompanying warrants. The offering includes the option for pre-funded warrants to purchase common stock. Oppenheimer & Co is acting as the sole book-running manager, with Newbridge Securities as co-manager.

The offering is subject to market conditions, and details regarding size and terms are not yet finalized. A shelf registration statement for this offering has been filed with the SEC and declared effective. The company will make the offering available through a prospectus supplement and accompanying prospectus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
49.61%
Tags

FAQ

What is the current stock price of Cue Biopharma (CUE)?

The current stock price of Cue Biopharma (CUE) is $0.6751 as of April 4, 2025.

What is the market cap of Cue Biopharma (CUE)?

The market cap of Cue Biopharma (CUE) is approximately 47.0M.

What is the primary focus of Cue Biopharma Inc?

Cue Biopharma Inc is focused on developing a novel class of biologic drugs that selectively modulate disease-specific T cells to treat a range of cancers and autoimmune disorders.

How does the Immuno-STAT platform work?

The Immuno-STAT platform involves engineering biologics that present specific peptides to activate and expand disease-specific T cells, thereby offering targeted therapeutic effects while minimizing adverse off-target immune responses.

Which therapeutic areas does the company target?

The company targets both oncology and autoimmune diseases, with specific programs addressing cancers such as head and neck squamous cell carcinoma and disorders associated with inflammatory and autoimmune conditions.

How does Cue Biopharma generate revenue?

Revenue is primarily generated through strategic collaborations with industry partners and through milestones achieved during the clinical development of its product candidates.

What differentiates Cue Biopharma from its competitors?

Cue Biopharma differentiates itself by leveraging its proprietary platform that enables selective modulation of T cells, potentially reducing systemic side effects and accelerating the drug development process.

What role does clinical research play in the company’s strategy?

Clinical research is central to the company’s strategy; rigorous phase 1 studies and combination therapy trials help establish both the safety and efficacy profiles of its novel biologics.

What is the significance of strategic partnerships for Cue Biopharma?

Strategic partnerships allow Cue Biopharma to leverage external expertise and resources, facilitating accelerated clinical development, resource sharing, and broader validation of its innovative therapeutic approach.

How does the company ensure operational efficiency in drug development?

By utilizing a modular and flexible platform for rapid peptide exchange within established drug frameworks, the company streamlines its development process, potentially reducing time and costs compared to traditional methodologies.
Cue Biopharma Inc

Nasdaq:CUE

CUE Rankings

CUE Stock Data

46.98M
61.47M
0.55%
18.58%
1.51%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON